**Table E7. Data abstraction of randomized controlled trials of SMRs**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Country Number of Centers and Setting** | **Inclusion Criteria** | **Number Randomized, Analyzed Attrition** | **Intervention** | **Study Participants** | **Duration of Pain (acute, subacute, chronic)** | **Duration of**  **Followup** |
| Pareek, 2009 | India  Multicenter | Age 18-70 with acute  low back pain and VAS score ≥6 at baseline (scale 0-10)  Excluded: sciatica or other underlying spinal disorder, malignancy, osteoporosis | Randomized: 197  Analyzed: 185  Attrition: 6% (12/197) | A. Tizanidine 2 mg +  aceclofenac 100 mg bid for 7 days (n=101) B. Aceclofenac 100 mg bid for 7 days (n=96) | A vs. B  Mean age 62 vs. 58 years  39% vs. 40% female  Race not reported  Baseline pain, function not reported | Acute/subacute; mean  duration not reported but inclusion criteria  required <30 days pain | 7 days |
| Ralph, 2008 | United States  Multicenter | Age 18-65 years with  moderate to severe acute low back pain ≤3 days  Excluded: duration >3 days, sciatica, history of spinal pathology, neurologic symptoms, chronic low back pain, osteoporosis | Randomized: 562  Analyzed: 547 for efficacy, 561 for safety  Attrition: efficacy  3% (15/547); safety 0.2% (1/561) | A. Carisoprodol 250  mg QID for 7 days  (n=277)  B. Placebo QID for 7 days (n=285 | A vs. B  Mean age 39 vs. 42 years  49% vs. 55% female Race: 74% vs. 77% Caucasian; 15% vs. 12% African; 10% vs. 10% Asian;  0.7% vs. 0.4% Native American; 0.4% vs. 0.4% other Baseline pain severity: mild  0.4% vs. 0.4%; moderate 74% vs. 74%; severe 25% vs. 26% Baseline RDQ 10 vs. 10 | Acute; mean duration 2  vs. 2 days | 7 days |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, Year** | **Results** | **Adverse Events Including**  **Withdrawals** | **Funding Source** | **Quality**  **Rating** |
| Pareek, 2009 | A vs. B  Pain at rest, mean change from baseline day 3: -3.01 vs. -1.90, p=0.0001;  day 7 -5.88 vs. -4.35, p=0.0001  Pain with movement, mean change from baseline day 3: -2.94 vs. -1.81, p=0.0001; day 7 -6.09 vs. -3.98, p=0.0001  Global improvement, proportion of patients reporting good or excellent response: 75% (71/94) vs. 34% (31/94); RR 1.28 (95% CI 1.07 to 1.52) | A vs. B  No serious adverse events in either group  Vomiting: 5% (5/101) vs. 7% (7/96); RR  0.68 (95% CI 0.22 to 2.07)  Dizziness: 5% (5/101) vs. 4% (4/96); RR  1.19 (95% CI 0.33 to 4.29) | Ipca Laboratories | Fair |
| Ralph, 2008 | A vs. B  Pain, patient-rated impression of pain relief, mean change from baseline day  3 (scale 0-4; higher score = greater pain relief): 1.8 vs. 1.1, p<0.0001; day 7 between-group difference p<0.0001 (data not shown)  Global improvement, patient-rated impression of change, mean change from baseline at day 3 (scale 0-4; higher score = greater improvement); 2.3 vs.  1.7, p<0.0001; day 7 between-group difference p<0.0001 (data not shown) | A vs. B  No serious adverse events in either group  Withdrawals due to adverse events: 3% (8/277) vs. 2% (5/284); RR 1.64 (95% CI  0.54 to 4.95)  Drowsiness: 13% (37/277) vs. 5% (13/284); RR 2.92 (95% CI 1.59 to 5.37) Dizziness: 10% (27/277) vs. 3% (9/284); RR 3.08 (95% CI 1.47 to 6.42) Headache: 4% (10/277) vs. 1% (4/284); RR 2.56 (95% CI 0.81 to 8.08) | MedPointe  Pharmaceuticals | Fair |

**Please see Appendix C. Included Studies for full study references.**